Stereotaxis Receives Second Odyssey Vision™ System Orders from Two Leading Heart Hospitals

ST. LOUIS, July 11, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has secured second Odyssey Vision^™ system orders from McLaren Bay Region Hospital in Michigan and Abrazo Arizona Heart Institute. Ranked among the top 10% in the nation for coronary interventional procedures by Healthgrades, McLaren Bay Region began utilizing the Odyssey Vision in September 2013. Arizona Heart Institute, a world-renowned destination for heart and vascular care, purchased its first Odyssey Vision system in March 2012.

“We are continually looking for ways to learn and grow in the ever changing field of electrophysiology (EP) to improve patient quality of life,” said Magen Samyn, Vice President, Marketing & Business Development at McLaren Bay Region. “The demonstrated performance of the Odyssey Vision system in our EP laboratory confirms that it is the consummate solution for enhancing our decision making and delivery of treatment options. We will continue to rely on its broad capabilities to service a growing demand for EP therapies.” 

Part of the Odyssey^® suite of products, the Odyssey Vision system aggregates and integrates the vast amount of clinical information during an EP procedure into one large screen, with a single mouse and keyboard control. This unique design allows the physician to focus on a consolidated view when controlling the various systems employed in the procedure, such as ultrasound, electrocardiogram and 3D mapping, to maximize procedure performance and efficiency. More than 125 institutions worldwide utilize the Odyssey Vision system.

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com. 

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:                                                                          
David Fischel
Chairman and Acting Chief Executive Officer

Martin C. Stammer                                                                             
Chief Financial Officer

[email protected]